Nantes, France, April 15, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results